Abatacept and Non-severe relapsing GPA

Abatacept and Non-severe relapsing GPA

An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s) 
Authors:  Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, Ytterberg SR, Hoffman GS, Krischer JP, Merkel PA; for the Vasculitis Clinical Research Consortium.

Abstract

Objectives:
 
To determine the safety and efficacy of abatacept in non-severe relapsing granulomatosis with polyangiitis (Wegener’s)(GPA). 

Methods:
 An open-label trial of intravenous abatacept was conducted in 20 patients with non-severe relapsing GPA. Prednisone up to 30 mg daily was permitted within the first 2 months, and patients on methotrexate, azathioprine, or mycophenolate mofetil continued these agents. Patients remained on study until common closing or early termination.

Results:
 O
f the 20 patients, 18 (90%) had disease improvement, 16 (80%) achieved remission (BVAS/WG=0) at a median of 1.9 months, and 14 (70%) reached common closing. Six patients (30%) met criteria for early termination due to increased disease activity; 3 of 6 achieved remission and relapsed at a median of 8.6 months. The median duration of remission before common closing was 14.4 months, with the median duration of time on study for all patients being 12.3 months (range 2-35 months). Eleven of the 15 (73%) patients on prednisone reached 0 mg. Nine severe adverse events occurred in 7 patients, including 7 infections that were successfully treated.

Conclusions:
 
In this study of patients with non-severe relapsing GPA, abatacept was well tolerated and was associated with a high frequency of disease remission and prednisone discontinuation.

January 2014
Source: 
Annals of the Rheumatic Diseases, The Eular Journal
Ann Rheum Dis. 2013 Dec 9. doi: 10.1136/annrheumdis-2013-204164


Fave_Icon_16x16